Literature DB >> 31699436

Postoperative pain control modalities for pectus excavatum repair: A prospective observational study of cryoablation compared to results of a randomized trial of epidural vs patient-controlled analgesia.

Charlene Dekonenko1, Robert M Dorman1, Yara Duran1, David Juang1, Pablo Aguayo1, Jason D Fraser1, Tolulope A Oyetunji1, Charles L Snyder1, George W Holcomb1, Daniel L Millspaugh2, Shawn D St Peter3.   

Abstract

BACKGROUND: Pain following bar placement for pectus excavatum is the dominant factor post-operatively and determines length of stay (LOS). We recently adopted intercostal cryoablation as our preferred method of pain control following minimally invasive pectus excavatum repair. We compared the outcomes of cryoablation to results of a recently concluded trial of epidural (EPI) and patient-controlled analgesia (PCA) protocols.
METHODS: We conducted a prospective observational study of patients undergoing bar placement for pectus excavatum using intercostal cryoablation. Results are reported and compared with those of a randomized trial comparing EPI with PCA. Comparisons of medians were performed using Kruskal-Wallis H tests with alpha 0.05.
RESULTS: Thirty-five patients were treated with cryoablation compared to 32 epidural and 33 PCA patients from the trial. Cryoablation was associated with longer operating time (101 min, versus 58 and 57 min for epidural and PCA groups, p < 0.01), resulted in less time to pain control with oral medication (21 h, versus 72 and 67 h, p < 0.01), and decreased LOS (1 day, versus 4.3 and 4.2 days, p < 0.01).
CONCLUSION: Intercostal cryoablation during minimally invasive pectus excavatum repair reduces LOS and perioperative opioid consumption compared with both EPI and PCA. LEVEL OF EVIDENCE: II.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cryoablation; Cryoanalgesia; Minimally invasive pectus excavatum repair

Mesh:

Year:  2019        PMID: 31699436     DOI: 10.1016/j.jpedsurg.2019.09.021

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

Review 1.  Intercostal Cryoneurolysis.

Authors:  Junjian Huang; Kevin Delijani; Husamuddin El Khudari; Andrew J Gunn
Journal:  Semin Intervent Radiol       Date:  2022-06-30       Impact factor: 1.780

2.  Early application of cryoanalgesia to the brachial plexus prevents development of phantom limb pain after traumatic forequarter amputation: A case report.

Authors:  Lizabeth A O'Connor; Bryan Houseman; Daniel Taffe; Curtis C Quinn
Journal:  Trauma Case Rep       Date:  2022-07-13

3.  A New Device for Thoracoscopic Cryoanalgesia in Pectus Excavatum Repair: Preliminary Single Center Experience.

Authors:  Michele Torre; Leila Mameli; Rachele Bonfiglio; Vittorio Guerriero; Lucia Derosas; Loredana Palomba; Nicola Disma
Journal:  Front Pediatr       Date:  2021-01-18       Impact factor: 3.418

Review 4.  Clinical Update on Patient-Controlled Analgesia for Acute Postoperative Pain.

Authors:  Cyrus Motamed
Journal:  Pharmacy (Basel)       Date:  2022-01-27

5.  Limited cryoablation reduces hospital stay and opioid consumption compared to thoracic epidural analgesia after minimally invasive repair of pectus excavatum.

Authors:  Seung Hwan Song; Duk Hwan Moon; Yon Hee Shim; Hyunjoo Jung; Sungsoo Lee
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

6.  Efficacy of intercostal cryoneurolysis as an analgesic adjunct for chest wall pain after surgery or trauma: systematic review.

Authors:  Peter I Cha; Jung Gi Min; Advait Patil; Jeff Choi; Nishita N Kothary; Joseph D Forrester
Journal:  Trauma Surg Acute Care Open       Date:  2021-05-18

7.  Intercostal nerve cryoablation is associated with lower hospital cost during minimally invasive Nuss procedure for pectus excavatum.

Authors:  Taylor J Aiken; Christopher C Stahl; Deborah Lemaster; Timothy W Casias; Benjamin J Walker; Peter F Nichol; Charles M Leys; Daniel E Abbott; Adam S Brinkman
Journal:  J Pediatr Surg       Date:  2020-10-19       Impact factor: 2.549

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.